Allergan
News/ News/ Sales and Marketing
Allergan, Teva considering $5bn play to shake off opioid hangover
Phil Taylor
AbbVie, Allergan, litigation, opioid crisis, Teva
0 Comment
News/ News/ Sales and Marketing
Latest ABPI code breaches reveal the risk of ‘likes’ on LinkedIn
Phil Taylor
ABPI, Allergan, AstraZeneca, Britannia Pharma, GlaxoSmithKline, PMCPA, Sanofi
0 Comment
News/ News/ Sales and Marketing
AbbVie prices first presbyopia drug Vuity at $80 per month
Phil Taylor
AbbVie, Allergan, ophthalmology, presbyopia, pricing, Vuity
0 Comment
AbbVie claims first FDA okay for presbyopia drug therapy
Phil Taylor
AbbVie, Allergan, fda, ophthalmology, presbyopia, regulatory approval
0 Comment
Allergan builds case for first drug therapy for presbyopia
Phil Taylor
AbbVie, Allergan, Eyenovia, LENZ Therapeutics, Novartis, Ocuphire, ophthalmology, Orasis Pharma, presbyopia, Visus Therapeutics
0 Comment
News/ News/ Sales and Marketing/ Top stories
Ex-Allergan CEO Saunders pops up again in ‘blank cheque’ company
Phil Taylor
Allergan, Brent Saunders, M&A, SPAC, Vesper Healthcare Acquisition
0 Comment
News/ News/ Sales and Marketing
Saunders steps aside as AbbVie closes in on Allergan merger
Phil Taylor
AbbVie, Allergan, Mergers and acquisitions, regulatory
0 Comment
First patient dosed in trial of Allergan/Editas’ CRISPR blindness drug
Phil Taylor
Allergan, blindness, CRISPR/Cas9, Editas, gene editing, Leber’s Congenital Amaurosis, ophthalmology
0 Comment